StockData

Conmed vs Haemonetics

CNMD and HAE side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CNMD and HAE compare

Haemonetics is the larger company, worth 3.8 times as much as Conmed ($5.5B against $1.5B).

On earnings, Conmed is cheaper: it trades at 20.4× trailing earnings, against 59.2× for Haemonetics.

Conmed grew revenue faster over the last twelve months (1.6% versus 0.44% for Haemonetics).

Haemonetics keeps more of each dollar of sales as profit, with a net margin of 7.1% compared with 5.4% at Conmed.

Conmed scores higher on the StockData Score (14 against 7 for Haemonetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCNMDHAE
Size and price
Market cap$1.5B$5.5B
Share price$49.35$121.34
Change, 1 year14.1%64.2%
Change, 5 years−63.5%134%
Beta (5Y)0.350.57
Employees3,900–
StockData Score
Total score14 (better)7
Valuation score6 (better)0
Growth score2 (better)1
Performance score4 (better)3
Health score23 (better)
Dividend score00
Valuation
P/E20.4× (better)59.2×
P/S1.1× (better)4.1×
P/B1.4× (better)6.6×
EV/EBITDA16.5× (better)23.9×
P/FCF11.1× (better)19.0×
FCF yield9.0% (better)5.3%
Fair value$67.98$69.95
Margin of safety27.4% (better)−73.5%
Growth
Revenue growth (TTM)1.6% (better)0.44%
Revenue growth, 5Y average9.8% (better)8.9%
Net income growth (TTM)14.6% (better)−41.1%
EPS growth (TTM)18.0% (better)−37.3%
EPS growth, 5Y average36.4% (better)5.8%
Profitability
Gross margin57.6%59.0% (better)
Operating margin9.9%11.9% (better)
Net margin5.4%7.1% (better)
FCF margin9.7%21.5% (better)
Return on equity7.1%11.2% (better)
Return on invested capital5.2%6.6% (better)
Financial health
Debt / equity0.77 (better)1.40
Net debt / EBITDA5.663.52 (better)
Interest coverage4.1×–
Current ratio1.493.08 (better)
Altman Z-score2.013.42 (better)
Piotroski F-score66
Dividends and buybacks
Dividend yield0.00%–
Payout ratio8.4%–
Years of dividend growth0–
Dividend growth, 5Y average−5.6%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions114%109%
Held by insiders0.47%1.8%
Insider net buying, 12 months$0 (better)−$101K
Short interest, % of float6.3%8.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.